Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line

Authors not listed

The Lymphoma Academic Research Organisation · 2009

Abstract

This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to explore the effect of maintenance therapy with lenalidomide versus placebo on progression-free survival (PFS) in patients treated with R-CHOP responding to induction therapy For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs 73.6%), is considered clinically relevant.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-04 MST

Cite this

APA
Anonymous. (2009). Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line. <em>The Lymphoma Academic Research Organisation</em>. https://clinicaltrials.gov/study/NCT01122472
Vancouver
Anonymous. Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line. The Lymphoma Academic Research Organisation. 2009.
BibTeX
@misc{anon2009Double, title = {Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line}, author = {Anonymous}, journal = {The Lymphoma Academic Research Organisation}, year = {2009}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings